Core Insights - CONMED Corporation (CNMD) reported adjusted earnings per share (EPS) of $1.43 for Q4 2025, a 6.7% increase year over year, surpassing the Zacks Consensus Estimate by 8.6% [1] - Full-year adjusted EPS was $4.59, reflecting a 10.1% increase from the previous year, also beating the Zacks Consensus Estimate by 2.2% [2] Revenue Performance - Q4 revenues reached $373.2 million, up 7.9% year over year, exceeding the Zacks Consensus Estimate by 1.9% [3] - Full-year revenues totaled $1.37 billion, a 5.2% improvement from the prior year, aligning with the Zacks Consensus Estimate [4] Segment Analysis - Orthopedic Surgery revenues in Q4 were $157.4 million, up 13.2% year over year [5] - General Surgery revenues were $215.8 million, reflecting a 4.3% increase year over year [6] Geographical Breakdown - Domestic revenues in Q4 amounted to $206.2 million, a 1.4% increase year over year [7] - International revenues reached $167 million, up 17% year over year [9] Margin and Expense Analysis - Gross profit for Q4 increased 10.1% year over year to $218.3 million, with gross margin expanding 116 basis points to 58.5% [10] - Total operating profit was $36.6 million, down 30.2% from the previous year, with operating margin contracting 536 basis points to 9.8% [11] Financial Position - Cumulative net cash provided by operating activities at the end of Q4 2025 was $170.7 million, compared to $166.9 million a year ago [12] Future Guidance - For 2026, total reported revenues are expected to be between $1,345 million and $1,375 million, with organic CER revenues projected to grow by 4.5%-6% [13] - Adjusted EPS for 2026 is projected to be in the range of $4.30-$4.45, with the Zacks Consensus Estimate at $4.52 [13] Overall Assessment - CONMED's Q4 results showed better-than-expected performance, with strong revenue growth from both product lines and improved gross margin [14] - Management highlighted strong momentum in high-growth platforms, indicating potential for future growth [15]